Alto Neuroscience (NYSE:ANRO) Posts Earnings Results, Beats Estimates By $0.09 EPS

Alto Neuroscience (NYSE:ANRO) issued its quarterly earnings data on Thursday. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.09, Zacks reports.

Alto Neuroscience Stock Down 4.0 %

NYSE ANRO traded down $0.11 during trading on Thursday, hitting $2.69. The stock had a trading volume of 207,871 shares, compared to its average volume of 359,519. The stock has a 50 day simple moving average of $3.70 and a 200 day simple moving average of $6.24. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. Alto Neuroscience has a one year low of $2.64 and a one year high of $18.35.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.